ePrints

Mechanisms that influence tumour response to VEGF-pathway inhibitors

Lookup NU author(s): Professor Steve Wedge

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

There has been significant investment in developing novel therapies to target solid tumour vasculature. Different technical approaches have been utilized with the aim of inhibiting tumour angiogenesis or compromising the function or stability of pre-existing tumour blood vessels. The vascular endothelial growth factor (VEGF) signalling axis remains the most widely studied, with biological and small-molecule therapeutics now registered for clinical use. However, despite these successes, the activity of these agents is not as widespread as was first postulated. The present review discusses the clinical successes of the VEGF inhibitors, the factors that may limit their utility, and the potential opportunities to maximize benefit from treatment with these agents in the future.

Publication metadata

Author(s): Smith NR, Wedge SR, Pommier A, Barry ST

Publication type: Article

Publication status: Published

Journal: Biochemical Society Transactions

Year: 2014

Volume: 42

Issue: 6

Pages: 1601-1607

Print publication date: 01/12/2014

Acceptance date: 23/09/2014

ISSN (print): 0300-5127

ISSN (electronic): 1470-8752

Publisher: Portland Press Ltd

URL: http://dx.doi.org/10.1042/BST20140261

DOI: 10.1042/BST20140261

Altmetrics

Share